摘要:
Novel compositions for the treatment of IRDS and ARDS are indicated which contain a compound of formula (I), in which R1 is hydrogen or 2-(2-hydroxyethoxy)ethyl and/or a pharmacologically tolerable salt of this compound and lung surfactant.
摘要:
The invention describes a set for the treatment of IRDS, ALI or ARDS, comprising a first container which has a volume of 50 to 500 ml and contains a pulverulent pulmonary surfactant preparation, the amount of phospholipids in the container being 50 to 500 mg, and a second container which has a volume of 50 to 500 ml and contains a pulverulent pulmonary surfactant preparation, where the amount of phospholipids in the second container is 1 to 10 g.
摘要:
The invention relates to compounds of formula (I) wherein R1, R2, R3, R4 and Y have the meanings given in the description. Said compounds are novel active bronchial therapeutic agents.
摘要:
Composition for the treatment of infant or adult respiratory distress syndrome (IRDS and ARDS) contains N-(3,5-dichloropyrid-4-yl)-3- cyclopropylmethoxy-4- difluoromethoxybenzamide (II) (and/or its salts) and a lung surfactant.
摘要:
The invention relates to the combined use of the PDE4 inhibitor N- (3,5-dichloropyrid-4-yl)- 3-cyclopropylmethoxy- 4-difluoromethoxybenzamide, its pharmacologically tolerable salts or its N- oxide with a PDE3 inhibitor for the treatment of certain disease conditions such as, for example, acute or chronic obstructions of the bronchi.
摘要:
Novel compositions are disclosed for the treatment of IRDS and ARDS, containing at least one glucocorticosteroid and a pulmonary surfactant. The duration of treatment and the mortality associated with these syndromes can be significantly reduced with the proposed novel compositions.
摘要:
The invention relates to the combined administration of PDE inhibitors and β2 adrenoceptor agonists for the treatment of respiratory tract disorders.
摘要:
The invention concerns the compounds 8,9-Diethoxy-2-methyl-6- [4(p-toluenesulfonamido)phenyl] -1,2,3,4,4a,10b-hexahydrobenzo[c] [1,6]naphthyridine and 9-Ethoxy-8-methoxy-2- methyl-6-[4-(p-toluenesulfonamido) phenyl]-1,2,3,4,4a,10b-hexahydrobenzo [c][1,6]naphthyridine and their therapeutic application.